Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


August 29, 2015 3:43 AM ET

Biotechnology

Company Overview of BioTime, Inc.

Executive Profile

Pedro Lichtinger

Chief Executive Officer of Asterias Biotherapeutics Inc and President of Asterias Biotherapeutics Inc, BioTime, Inc.
AgeTotal Calculated CompensationThis person is connected to 3 Board Members in 3 different organizations across 5 different industries.

See Board Relationships
61$2,172,229
As of Fiscal Year 2014

Background

Mr. Pedro Lichtinger has been the Chief Executive Officer and President of Asterias Biotherapeutics, Inc. since June 09, 2014. Mr. Lichtinger served as the Chief Executive Officer and President of Optimer Pharmaceuticals, Inc. from May 2010 to February 2013. Mr. Lichtinger served as an Executive of Pfizer, Inc. from 1995 to 2009 and as the President of Pfizer's Global Primary Care Business Unit from 2008 to 2009, Area President, Europe from 2006 to 2008, President, Global ...

Corporate Headquarters

1301 Harbor Bay Parkway
Alameda, California 94502

United States

Phone: 510-521-3390
Fax: 510-521-3389

Board Members Memberships

Member of Board of Governors
2014-Present
Chief Executive Officer, President and Director

Education

MBA 1978
University of Pennsylvania - The Wharton School
BE
Universidad Nacional Autónoma de México

Other Affiliations

Annual Compensation

Salary$224,359
Total Annual Compensation$224,359

Stocks Options

Restricted Stock Awards$468,000
All Other Compensation$8,333
Exercisable Options$125,000
Unexercisable Options$875,000
Total Number of Options$1,000,000

Total Compensation

Total Annual Cash Compensation$270,942
Total Short Term Compensation$224,359
Other Long Term Compensation$476,333
Total Calculated Compensation$2,172,229
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Olav Hellebo Chief Executive Officer and Director
ReNeuron Group plc
$225.0K
Paul K. Wotton Ph.D.Chief Executive Officer, President and Director
Ocata Therapeutics, Inc.
$243.3K
I. Richard Garr J.D.Co-Founder, Chief Executive Officer, President, General Counsel and Director
Neuralstem, Inc.
$651.2K
Yokoyama Chikafumi Ph.D.Chief Executive Officer, President and Representative Director
ReproCELL, Inc.
--
Keith Murphy Chairman, Chief Executive Officer, President, Member of Audit Committee and Member of Science & Technology Committee
Organovo Holdings, Inc.
$469.9K
Compensation as of Fiscal Year 2015.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact BioTime, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.